FDA Provides Positive Phase 3 Guidance for LLY-Partnered Oral Osteoporosis Drug
What happened
Entera Bio, which holds a licensing and development agreement with Eli Lilly (LLY), announced it received positive FDA feedback on its proposed Phase 3 trial design for EB613, an oral parathyroid hormone pill targeting osteoporosis. The agency's response supports the study's primary endpoint structure and patient population parameters. No Phase 3 start date was disclosed. The program represents a potential oral alternative to injectable PTH therapies currently on the market.
The QL Read
LLY's composite sits at a neutral 49/100 with a modest +1.68% day move — partner-level regulatory news is unlikely to shift that read materially. Broader tape context adds caution: with only 26% of stocks advancing today, the market is not rewarding speculative pipeline catalysts.